文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

作者信息

Ramsay Alan G, Johnson Amy J, Lee Abigail M, Gorgün Güllü, Le Dieu Rifca, Blum William, Byrd John C, Gribben John G

机构信息

Institute of Cancer, Centre for Medical Oncology, Barts and The London School of Medicine, University of London, London, United Kingdom.

出版信息

J Clin Invest. 2008 Jul;118(7):2427-37. doi: 10.1172/JCI35017.


DOI:10.1172/JCI35017
PMID:18551193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2423865/
Abstract

Cancer is associated with immune deficiency, but the biologic basis of this is poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation with APCs. Although this synapse dysfunction was in part a result of the CLL cells having poor APC function, defective actin polymerization was also identified in T cells from patients with CLL. We further demonstrate that, following contact with CLL cells, defects in immune synapse formation were induced in healthy allogeneic T cells. This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells. In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells, recruitment of key regulatory proteins to the immune synapse was inhibited. Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation. These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches.

摘要

相似文献

[1]
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

J Clin Invest. 2008-7

[2]
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Blood. 2012-4-30

[3]
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.

Cancer Immunol Res. 2016-8

[4]
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Blood. 2013-1-16

[5]
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.

Proc Natl Acad Sci U S A. 2009-4-14

[6]
T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Blood. 2002-7-1

[7]
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo.

Cytotherapy. 2009

[8]
CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.

Blood. 1999-3-15

[9]
Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.

Clin Cancer Res. 2003-5

[10]
Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.

Cancer. 2011-2-24

引用本文的文献

[1]
Neutrophils unveiled in chronic lymphocytic leukemia.

Front Immunol. 2025-8-20

[2]
Immunological synapse formation as a key mechanism in T cell-dependent bispecific antibody-mediated immune activation and cytotoxicity.

Cancer Immunol Immunother. 2025-6-21

[3]
A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation.

Front Immunol. 2025-5-29

[4]
Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia.

Front Cell Dev Biol. 2025-4-17

[5]
The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia.

Biomedicines. 2025-4-4

[6]
Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL.

Blood Adv. 2025-6-24

[7]
Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia.

Haematologica. 2025-8-1

[8]
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.

Target Oncol. 2025-3

[9]
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia.

Cell Mol Immunol. 2025-5

[10]
Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0.

Cancers (Basel). 2025-1-21

本文引用的文献

[1]
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

J Clin Oncol. 2008-5-20

[2]
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Blood. 2008-6-1

[3]
Lenalidomide for the treatment of B-cell malignancies.

J Clin Oncol. 2008-3-20

[4]
Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.

Cancer Res. 2007-12-1

[5]
The role of the integrin LFA-1 in T-lymphocyte migration.

Immunol Rev. 2007-8

[6]
Immune surveillance of tumors.

J Clin Invest. 2007-5

[7]
Harnessing the immune system to treat cancer.

J Clin Invest. 2007-5

[8]
Modulation of the immunological synapse: a key to HIV-1 pathogenesis?

Nat Rev Immunol. 2007-4

[9]
Regulation of T-cell activation by the cytoskeleton.

Nat Rev Immunol. 2007-2

[10]
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

J Clin Oncol. 2006-12-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索